Zimmer Biomet Holdings Inc. (NYSE:ZBH) has a beta of 1.36, a 12-month trailing P/E ratio of 61.36, and a growth ratio of 5.43. The stock’s Relative Strength Index (RSI) is 42.54, with weekly volatility at 1.57% and ATR at 3.11. The ZBH stock’s 52-week price range has touched low of $112.00 and a $180.36 high. Its shares traded higher over the last trading session, gaining 0.44% on 05/18/21. The shares fell to a low of $165.74 before closing at $166.54. Intraday shares traded counted 0.86 million, which was 23.52% higher than its 30-day average trading volume of 1.12M. ZBH’s previous close was $165.81 while the outstanding shares total 208.00M.
Investors have identified the Medical Devices company Zimmer Biomet Holdings Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $34.38 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Zimmer Biomet Holdings Inc. (ZBH) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For ZBH, the company has in raw cash 724.3 million on their books with 300.0 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on a decline. In terms of their assets, the company currently has 5.0 billion total, with 2.09 billion as their total liabilities.
Having a look at the company’s valuation, the company is expected to record 8.69 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on ZBH sounds very interesting.
Is the stock of ZBH attractive?
In related news, Director, HIGGINS ARTHUR J bought 1,000 shares of the company’s stock in a transaction that recorded on May 06. The purchase was performed at an average price of 171.58, for a total value of 171,580. As the purchase deal closes, the President, Asia Pacific, Yi Sang now sold 1,200 shares of the company’s stock, valued at 183,108. Also, Sr. VP/Gen Counsel/Secretary, Phipps Chad F sold 30,040 shares of the company’s stock in a deal that was recorded on Nov 09. The shares were cost at an average price of 159.70 per share, with a total market value of 4,797,388. Following this completion of disposal, the President, Asia Pacific, Yi Sang now holds 3,000 shares of the company’s stock, valued at 376,130. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.10%.
22 out of 30 analysts covering the stock have rated it a Buy, while 4 have maintained a Hold recommendation on Zimmer Biomet Holdings Inc.. 1 analysts has assigned a Sell rating on the ZBH stock. The 12-month mean consensus price target for the company’s shares has been set at $186.08.